Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion is a promising clinical stage diabetes and obesity medicines company with a positive outlook due to its two main drug candidate programs: icovamenib, a selective inhibitor of menin, and BMF-650, a next-generation GLP-1 receptor agonist. Icovamenib has shown effectiveness in improving insulin secretion and A1c levels in clinical trials, with potential launch in 2030 for a large market opportunity. The company is also addressing financial risks and has a potential disease-modifying treatment in a competitive market.

Bears say

Biomea Fusion is a clinical-stage biotech company focused on developing small molecule drugs for diabetes and obesity. However, while its lead candidate, icovamenib, has shown promising results in early trials, the drug's effectiveness has yet to be confirmed in larger patient populations and its mechanism of action may be sensitive to patient selection and other factors. Additionally, the company faces competition from established diabetes and obesity treatments, which may limit the commercial potential of its drugs.

BMEA has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Strong Buy based on their latest research and market trends.

According to 3 analysts, BMEA has a Strong Buy consensus rating as of Sep 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.